Workflow
富达悦享红利优选混合A
icon
Search documents
主动权益全优答券,外资公募巨头超额收益之道
Xin Lang Cai Jing· 2026-01-21 11:18
Market Overview - The A-share market has shown a strong start in 2026, with the Shanghai Composite Index achieving a 17-day winning streak and trading volume exceeding 3.64 trillion [1] - The active equity funds have consistently outperformed broad indices, with the Wind Active Equity Fund Index rising by 33.19% in 2025, significantly surpassing the 17.66% increase of the CSI 300 [1] Fund Performance - Fidelity's active equity funds have outperformed their benchmarks across both short-term and medium-term dimensions, with notable performances including Fidelity Heritage 6-Month A returning 65.71%, exceeding its benchmark by 42.04% [2][3] - Fidelity Heritage A has achieved a return of 59.76% since its inception on April 25, 2023, significantly outperforming its benchmark of 19.87% [2][3] Fund Manager Insights - Fidelity's fund managers, including Zhang Xiaomu, have demonstrated strong performance, with returns exceeding 10% across all managed products in 2026 [8][9] - Zhang Xiaomu's management of Fidelity Heritage has resulted in a 76.90% return over the past year, outperforming the benchmark by over 50% [9] Investment Strategy - Fidelity emphasizes a bottom-up investment approach, focusing on deep research and understanding of companies, which has been a hallmark of its investment philosophy since the era of Peter Lynch [4][19] - The firm has developed a diverse product matrix to meet varying client needs, including flagship, dividend, and growth series products [5][6] Manager Development - Fidelity's rigorous training program for fund managers spans over a decade, ensuring they gain comprehensive industry experience and develop their investment styles [17][18] - The firm employs a unique fund manager academy to facilitate the transition from research to investment, providing practical training and mentorship [17][18]
基金分红:富达悦享红利优选混合基金12月15日分红
Sou Hu Cai Jing· 2025-12-09 01:36
Core Viewpoint - The announcement details the second dividend distribution for the Fidelity Enjoy Dividend Preferred Mixed Securities Investment Fund for the year 2025, with specific dates and amounts outlined for investors [1]. Dividend Distribution Details - The dividend distribution base date is set for December 12, 2025, with the following dividend scheme: - Fidelity Enjoy Dividend Preferred Mixed A (Code: 020493) has a net asset value of 1.19 yuan and will distribute 0.28 yuan per 10 shares - Fidelity Enjoy Dividend Preferred Mixed C (Code: 020494) has a net asset value of 1.17 yuan and will also distribute 0.28 yuan per 10 shares [1]. Eligibility and Payment Information - The dividend recipients are all fund shareholders registered with the fund's registration agency as of the equity registration date, which is December 11, 2025. The cash dividend payment date is December 15, 2025 [1]. - For investors opting for the dividend reinvestment method, the reinvestment shares will be calculated based on the fund's net asset value on December 11, 2025. Confirmation of the reinvestment shares will occur on December 12, 2025, and these shares can be queried and redeemed starting December 15, 2025 [1]. Tax and Fee Information - According to regulations from the Ministry of Finance and the State Administration of Taxation, the fund's income distributed to investors is temporarily exempt from income tax. Additionally, there are no fees for the dividend distribution, and reinvestment shares are exempt from subscription fees [1].
中国神华股价连续6天上涨累计涨幅6.54%,中国富达基金旗下1只基金持22.6万股,浮盈赚取56.73万元
Xin Lang Cai Jing· 2025-10-15 07:29
Group 1 - China Shenhua's stock price increased by 0.52% to 40.86 CNY per share, with a trading volume of 1.545 billion CNY and a market capitalization of 811.828 billion CNY as of October 15 [1] - The stock has risen for six consecutive days, with a cumulative increase of 6.54% during this period [1] - The company's main business segments include coal (75.23%), power generation (29.35%), rail transport (15.52%), port operations (2.51%), coal chemical (2.11%), and shipping (1.19%) [1] Group 2 - Fidelity's fund, "Fidelity Enjoys Dividend Preferred Mixed A" (020493), holds 226,000 shares of China Shenhua, representing 4.14% of the fund's net value, making it the ninth-largest holding [2] - The fund has realized a floating profit of approximately 47,500 CNY today and 567,300 CNY during the six-day increase [2] - The fund has a total asset size of 49.288 million CNY and has achieved a year-to-date return of 24.58% [2] Group 3 - The fund manager, Nie Yixiang, has been in position for 8 years and 76 days, with a total asset size of 30.7 million CNY and a best return of 135.58% during his tenure [3] - Co-manager Zhou Wenqun has been in position for 2 years and 175 days, managing assets of 48.2 million CNY with a best return of 39.09% [3]
富达悦享红利优选混合A:2025年上半年利润755.47万元 净值增长率10.19%
Sou Hu Cai Jing· 2025-09-05 09:33
Core Viewpoint - The AI Fund Fidelity Enjoy Dividend Preferred Mixed A (020493) reported a profit of 7.5547 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.0873 yuan, and a net asset value growth rate of 10.19% during the same period [2]. Fund Performance - As of September 3, the fund's net asset value growth rate over the past three months was 16.30%, ranking 384 out of 607 comparable funds; over the past six months, it was 22.44%, ranking 237 out of 607; and over the past year, it was 25.69%, ranking 500 out of 604 [4]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 7.05 times, compared to the industry average of 33.74 times; the weighted average price-to-book (P/B) ratio was about 0.5 times, against an industry average of 2.47 times; and the weighted average price-to-sales (P/S) ratio was around 0.98 times, while the industry average was 2.07 times, indicating that all three valuation metrics are below the industry average [9]. Growth Metrics - For the first half of 2025, the weighted average year-on-year revenue growth rate (TTM) of the stocks held by the fund was 0.05%, and the weighted average net profit growth rate (TTM) was 0.03%, with a weighted annualized return on equity of 0.07% [15]. Fund Size and Shareholder Composition - As of June 30, 2025, the fund's total size was 49.2887 million yuan, with 839 holders collectively owning 46.5021 million shares. Management employees held 531,100 shares, accounting for 1.14%, while individual investors held 100% of the shares [31][34]. Trading Activity - The fund's turnover rate over the last six months was approximately 140.96%, which is consistently lower than the industry average [37].
外资公募最新持仓出炉 深挖A股结构性机会
Core Insights - Foreign public funds have shown strong performance in Q2, with a focus on structural opportunities in the Chinese market, particularly in artificial intelligence, innovative pharmaceuticals, and high-dividend assets [1][2][3] Group 1: Fund Performance - Several foreign public equity products achieved notable returns in Q2, with the Robeco China Healthcare Equity Fund leading at a 28.51% increase in net value [1] - BlackRock's Advanced Manufacturing Fund and Fidelity's Dividend Growth Fund reported net value increases of 21.83% and 13.64%, respectively [1] Group 2: Investment Strategies - Robeco emphasized a multi-dimensional evaluation of companies in the innovative sector, focusing on quality, talent, R&D investment, and clinical data to select high-potential firms [1] - BlackRock's fund manager highlighted a strategic focus on artificial intelligence and technology sectors, achieving significant excess returns [2] - Fidelity's managers noted strong performance in traditional dividend sectors, attracting risk-averse capital due to low valuations and high dividend certainty [2] Group 3: Future Outlook - Fund managers expressed optimism about the attractiveness of A-share valuations, supported by policy backing and positive industry trends, indicating ongoing structural opportunities [2] - Future investment will continue to prioritize high-quality technology assets and sectors with concentrated distribution, such as TMT, machinery, pharmaceuticals, and chemicals [3] - The Chinese pharmaceutical industry is expected to enhance its global competitiveness, with a clear trend towards international expansion in innovative drugs and medical devices [3]